دورية أكاديمية
DNA methylation of selected tumor suppressor genes in endometrial hyperplasia.
| العنوان: | DNA methylation of selected tumor suppressor genes in endometrial hyperplasia. |
|---|---|
| المؤلفون: | Dvorak O; Department of Obstetrics and Gynecology, University Hospital Hradec Kralove and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic., Ndukwe M; Department of Obstetrics and Gynecology, University Hospital Hradec Kralove and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic., Slavickova M; Department of Clinical Biochemistry and Diagnostics and Osteocenter, University Hospital Hradec Kralove and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic., Laco J; The Fingerland Department of Pathology, University Hospital Hradec Kralove and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic., Spacek J; Department of Obstetrics and Gynecology, University Hospital Hradec Kralove and Faculty of Medicine, Charles University, Hradec Kralove, Czech Republic. |
| المصدر: | Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia [Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub] 2024 Mar; Vol. 168 (1), pp. 68-73. Date of Electronic Publication: 2023 Jan 09. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Vydavatelství Univerzity Palackého Country of Publication: Czech Republic NLM ID: 101140142 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1804-7521 (Electronic) Linking ISSN: 12138118 NLM ISO Abbreviation: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1992- : Olomouc : Vydavatelství Univerzity Palackého Original Publication: Prague : Státní Pedagogické Nakladatelství, 1985- |
| مواضيع طبية MeSH: | Endometrial Hyperplasia*/genetics , Endometrial Hyperplasia*/pathology , Endometrial Neoplasms*/genetics , Endometrial Neoplasms*/pathology, Female ; Humans ; DNA Methylation/genetics ; Hyperplasia/genetics ; Genes, Tumor Suppressor ; DNA-Binding Proteins/genetics |
| مستخلص: | Aims: To investigate DNA methylation of specific gene promoters in endometrial hyperplasia compared to normal endometrial tissue. Materials and Methods: To search for epigenetic events, methylation-specific multiplex ligation-dependent probe amplification was employed to compare the methylation status of 64 tissue samples with atypical endometrial hyperplasia, 60 tissue samples with endometrial hyperplasia without atypia, and 40 control tissue samples with normal endometrium. Results: Differences in DNA methylation among the groups were found in PTEN, CDH13, and MSH6 promoters (PTEN: atypical hyperplasia 32%, benign hyperplasia 6.8%, normal endometrium 10%; P=0.004; CDH13: atypical hyperplasia, 50%; benign hyperplasia, 43%; normal endometrium 8.1%; P=0.003; MSH6 atypical hyperplasia 84%, benign hyperplasia, 62%; normal endometrium, 52%; P=0.008.) Higher rates of CDH13 promoter methylation were identified in the groups with both forms of endometrial hyperplasia when compared to the control group (atypical hyperplasia, P=0.003, benign hyperplasia, P=0.0002). A higher rate of DNA methylation of the PTEN and MSH6 promoters was observed in samples with atypical endometrial hyperplasia than in samples with benign endometrial hyperplasia (PTEN: P=0.02; MSH6: P=0.01) and samples with normal endometrial tissue (PTEN, P=0.04; MSH6, P=0.006). Conclusion: DNA methylation of CDH13, PTEN, and MSH6 appear to be involved in the development of endometrial hyperplasia. Competing Interests: The authors report no conflicts of interest in this work. |
| References: | Singh G, Puckett Y, Endometrial Hyperplasia, in StatPearls. 2022: Treasure Island (FL). Hsu YT, Gu F, Huang YW, Liu J, Ruan J, Huang RL, Wang CM, Chen CL, Jadhav RR, Lai HC, Mutch DG, Goodfellow PJ, Thompson IM, Kirma NB, Huang TH. Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res 2013;19(22):6272-85. (PMID: 10.1158/1078-0432.CCR-13-1734) Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol 2016;27(1):e8. (PMID: 10.3802/jgo.2016.27.e8) Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56(2):403-12. (PMID: 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X) Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59(5):368-78. (PMID: 10.1097/00006254-200405000-00025) Palmer JE, Perunovic B, Tidy JA. Endometrial hyperplasia. The Obstetrician & Gynaecologist 2008;10(4):211-16. (PMID: 10.1576/toag.10.4.211.27436) Litta P, Bartolucci C, Saccardi C, Codroma A, Fabris A, Borgato S, Conte L. Atypical endometrial lesions: hysteroscopic resection as an alternative to hysterectomy. Eur J Gynaecol Oncol 2013;34(1):51-3. Lacey JV, Jr., Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009;63(1):39-44. (PMID: 10.1016/j.maturitas.2009.02.005) Lacey JV, Jr., Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, Ronnett BM, Chatterjee N, Langholz B, Sherman ME, Glass AG. Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan. Int J Cancer 2012;131(8):1921-9. (PMID: 10.1002/ijc.27457) Nieminen TT, Gylling A, Abdel-Rahman WM, Nuorva K, Aarnio M, Renkonen-Sinisalo L, Jarvinen HJ, Mecklin JP, Butzow R, Peltomaki P. Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res 2009;15(18):5772-83. (PMID: 10.1158/1078-0432.CCR-09-0506) Moelans CB, Verschuur-Maes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011;225(2):222-31. (PMID: 10.1002/path.2930) Trimarchi MP, Yan P, Groden J, Bundschuh R, Goodfellow PJ. Identification of endometrial cancer methylation features using combined methylation analysis methods. PLoS One 2017;12(3):e0173242. (PMID: 10.1371/journal.pone.0173242) Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, Fukumoto M, Mak TW. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8(21):1169-78. (PMID: 10.1016/S0960-9822(07)00488-5) Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8(5):1178-84. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275(5308):1943-7. (PMID: 10.1126/science.275.5308.1943) Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100(4):387-90. (PMID: 10.1016/S0092-8674(00)80674-1) Li J, Gong P, Lyu X, Yao K, Li X, Peng H. Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker. Oncol Rep 2014;31(5):2206-12. (PMID: 10.3892/or.2014.3061) Sun D, Zhang Z, Van do N, Huang G, Ernberg I, Hu L. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Oral Oncol 2007;43(1):82-7. (PMID: 10.1016/j.oraloncology.2006.01.007) Sun Y, Hegamyer G, Cheng YJ, Hildesheim A, Chen JY, Chen IH, Cao Y, Yao KT, Colburn NH. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 1992;89(14):6516-20. (PMID: 10.1073/pnas.89.14.6516) Fendri A, Khabir A, Hadri-Guiga B, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R. Epigenetic alteration of the Wnt inhibitory factor-1 promoter is common and occurs in advanced stage of Tunisian nasopharyngeal carcinoma. Cancer Invest 2010;28(9):896-903. (PMID: 10.3109/07357907.2010.494324) Hui AB, Lo KW, Kwong J, Lam EC, Chan SY, Chow LS, Chan AS, Teo PM, Huang DP. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol Carcinog 2003;38(4):170-8. (PMID: 10.1002/mc.10156) Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol 2019;58(3):342-52. (PMID: 10.1080/0284186X.2018.1540886) Raffone A, Travaglino A, Saccone G, Campanino MR, Mollo A, De Placido G, Insabato L, Zullo F. Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2019;98(3):275-86. (PMID: 10.1111/aogs.13513) Abd El-Maqsoud NM, El-Gelany S. Differential Expression Patterns of PTEN in Cyclic, Hyperplastic and Malignant Endometrium: Its Relation with ER, PR and Clinicopathological Parameters. J Egypt Natl Canc Inst 2009;21(4):323-31. Orbo A, Nilsen MN, Arnes MS, Pettersen I, Larsen K. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia. Int J Gynecol Pathol 2003;22(2):141-8. (PMID: 10.1097/00004347-200304000-00005) Angst BD, Marcozzi C, Magee AI. The cadherin superfamily: diversity in form and function. J Cell Sci 2001;114(Pt 4):629-41. (PMID: 10.1242/jcs.114.4.629) Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 2009;1(6):a003129. (PMID: 10.1101/cshperspect.a003129) Lin YL, Gui SL, Ma JG. Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer. Oncol Lett 2015;10(2):647-52. (PMID: 10.3892/ol.2015.3337) Mostafavi-Pour Z, Kianpour S, Dehghani M, Mokarram P, Torabinejad S, Monabati A. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer. Pathol Oncol Res 2015;21(4):921-7. (PMID: 10.1007/s12253-015-9917-8) Chmelařová M, Křepinská E, Spaček J, Laco J, Nekvindová J, Palička V. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA. Folia Biol (Praha) 2012;58(6):246-50. Sheng Y, Wang H, Liu D, Zhang C, Deng Y, Yang F, Zhang T, Zhang C. Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma. Gynecol Oncol 2016;140(1):145-51. (PMID: 10.1016/j.ygyno.2015.11.017) |
| فهرسة مساهمة: | Keywords: CDH13; MSH6; PTEN; endometrial hyperplasia; epigenetics; methylation |
| المشرفين على المادة: | 0 (DNA-Binding Proteins) |
| تواريخ الأحداث: | Date Created: 20230111 Date Completed: 20240313 Latest Revision: 20240313 |
| رمز التحديث: | 20240313 |
| DOI: | 10.5507/bp.2022.053 |
| PMID: | 36628559 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1804-7521 |
|---|---|
| DOI: | 10.5507/bp.2022.053 |